Company profile
Vivos Therapeutics, Inc.
NASDAQ: VVOS · Healthcare · Medical - Devices
#571 of 1,422 Healthcare companies by revenue62nd-percentile growth
EA Score
38DFH 36DQ 28GM 62SS 47
v0.1 · 65/100 weight · provisional
↑ growth stability, workforce scale · ↓ filing timeliness, Piotroski F
Methodology →Revenue TTM
$19.6M
Rev growth YoY (TTM)
+33.8%
Net income (FY)
-$21.2M
Employees
268
as of 2026-08-24
Market cap
$4.1M
as of 2026-08-24
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$17.4M$17.4M2025
Net income-$21.2M-$21.2M2025
Operating income-$19.9M-$19.9M2025
Total assets$25.2M$25.2M2025
Liabilities$26.7M$26.7M2025
Equity-$1.5M-$1.5M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Service43%
Product26%
Appliances13%
Treatment Centers9%
Sponsorship Seminar Other5%
Billing Intelligence Services3%
By geography
Not disclosed.
The read
What is Vivos Therapeutics, Inc.’s revenue?
Vivos Therapeutics, Inc. booked $17.4M in FY2025 revenue, growing 16% year over year — faster than most Healthcare companies we track, at a -121.4% net margin.
Peers · Healthcare
ManifestSeven Holdings Corporation——Vibe Growth Corporation58CMicron Solutions, Inc.——Clever Leaves Holdings Inc.——Choom Holdings Inc.——Veru Inc.49DNeighbors
Arapahoe →Key facts
CEOR. Kirk Huntsman
SectorHealthcare
IndustryMedical - Devices
HeadquartersLittleton, CO
ExchangeNASDAQ: VVOS
Employees268
IPO date2020-12-11
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.